All
CURE Inaugural Commercial to Air During SU2C Telecast
September 7th 2018CURE Media Group, the nation’s leading digital and print media enterprise dedicated to patients and survivors of cancer, will launch its first television commercial featuring curetoday.com during the Stand Up To Cancer (SU2C) telecast tonight.
LOXO-292 Granted Breakthrough Therapy Designation for Lung and Thyroid Cancer
September 5th 2018The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC). This designation will expedite the development and review of the drug.
Experimental Drug Combination Shows Potential in Early-Phase Trial of Lung, Ovarian Cancers
September 4th 2018Researchers may have found a potential new way to treat patients with ovarian or lung cancer who had previously failed other treatments, according to early trial findings published in Annals of Oncology.
FDA Grants Keytruda Priority Review to Treat Rare Form of Skin Cancer
September 4th 2018The Food and Drug Administration (FDA) granted priority review to a new supplemental biologics license application for Keytruda (pembrolizumab) to treat adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma, according to Merck, the agent’s manufacturer.
Knowledge About Inherited Gene Mutations Is Changing Prostate Cancer Treatment
September 1st 2018Family history was one indicator that a man should undergo periodic screening, but it wasn’t until a couple of decades ago that scientists confirmed a link between inherited mutations of the BRCA gene and the development of prostate cancer.
Helping Others to Help Yourself Live Longer
August 31st 2018After we have been diagnosed with cancer, our lives will never be the same again. But we need to try to just perform one little service – a phone call, a card, an email to encourage others. The wonderful thing is with or without cancer, we may just live a little bit longer with joy!
New Test May Identify Those Unlikely to Respond to Popular Bladder Cancer Treatment
August 30th 2018While there is currently no definitive way to predict who will respond and who will not, researchers at Brighton and Sussex Medical School in the United Kingdom are working on a blood test that could identify about half of those who may not.